CARDIOVASCULAR JOURNAL OF AFRICA • PAFCIC 2021 Abstracts December 2021 27 AFRICA Submission ID: 1026 CLINICAL CHARACTERISTICS OF PATIENTS UNDERGOING TAVR Amira Talhaoui, SARRA CHENIK, Aymen NOOMEN, Yassine Jabloun, Abdeddayem Haggui, Nadhem Hajlaoui, wafa Fehri Tunisia Background: Percutaneous or transcatheter aortic valve replacement (TAVR) represents a real revolution in the treatment of symptomatic patients with severe and high-risk calcified aortic stenosis (ACR) or having a surgical contraindication. Methods: This is a retrospective single-center study whose objective was to study the clinical characteristics of 51 patients implanted with percutaneous aortic bio prosthesis in the Military Hospital of Tunis, conducted between November 2013 and February 2020. Results: Our population was made up of 29 men or 55% and 23 women or 45% with a sex ratio of 1.21 for the entire workforce and an average age of 78.88 ± 8 years. Most of the patients were overweight with an average body mass index of 27.18 kg / m². Regarding cardiovascular risk factors, thirteen patients were smoking, 40 hypertensive (83%), 23 diabetics (48%) and 21 dyslipidemia (44%). For other comorbidities, 43% of patients were anemic and 18 patients had pulmonary pathologies (COPD or asthma) with two cases at long lasting oxygen. One patient had renal failure on dialysis and 4 patients had a history of neoplasia in remission. Coronary artery disease was observed in 22 cases, or 43% of the population. Concerning the operative risk scores, twelve (24%) patients had a greater EUROSCORE than 20%, and 28 (55%) patients with an STS score greater than 10%. Conclusion: TAVR can treat effectively symptomatic aortic stenosis in patients at very high surgical risk or with surgical contrindication. The evaluation of the clinical characteristics of the patients proposed for TAVR makes it possible to better target patients likely to fully benefit from this therapy. MODERATED POSTER SESSION 2 Submission ID: 1117 COMPARISON OF SHORT- AND LONG-TERM MORTALITY OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION AND NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS Abdelmalek AZZOUZ, Omar AIT MOKHTAR, Maamar KARA, Adel AZAZA, Dahlia DJERMANE, Arezki SIK, Amine SALEM, Bilal GRINE, Ali BEDJAOUI, Fayçal MAKHLOUF, Salim BENKHEDDA Cardiology Department A2. Mustapha Hospital. Algiers, Algeria Introduction: Available data comparing long-term prognosis according to the type of coronary syndrome (ACS) are rare, old and sometimes contradictory. Purpose: Our objective is to compare in-hospital, short-term and long-term mortality in patients with STEMI vs NSTEMI ACS. Methods: All patients admitted for ACS in our cardiology department, consenting, between January 2018 and July 2019 with 12 months follow-up. Results: A total of 397 patients with ACS of whom 257 (64.6%) STEMI and 140 (35.4%) NSTEMI were included in the study. In-hospital mortality rates were 8.9% for patients admitted for STEMI and 1.4% for NSTEMI (p=0.006). At 30-day follow-up, mortality rates were 1.4% and 0.8% (p = 0.09) for STEMI and NSTEMI patients, respectively. At 12-month follow-up, mortality rates were 3.5% and 4.5% (p = 0.001) for STEMI and non-STEMI patients, respectively. Conclusion: STEMI patients have a worse in-hospital prognosis than non-STEMI patients, due to the prevalence of cardiogenic shock in this group of patients and the very long delays in management ( Mean PainPPCI delay= 545 minutes) . Within 30 days of ACS, patients in both groups had a similar prognosis. However, at 12 months, NSTEMI patients have a poor prognosis compared to STEMI patients, due to their advanced age and more prevalent comorbidities/risk factors compared to STEMI patients. Submission ID: 986 HYPERTROPHIC CARDIOMYOPATHY IN CHILDREN: ETIOLOGY AND CLINICAL CHARACTERISTICS Ben Othman Rihab, Hakim Kaouthar, Msaad Hela, Ghardallou Houda, Oueghlani Khalil, El Bardi Mouad, Karmous Rahma, Ftini Syrine, Ouarda Fatma pediatric cardiology department of the Rabta Hospital, Tunisia Background: Hypertrophic cardiomyopathy (HCM) represents the second most common cardiomyopathy in the pediatric population. The etiologies and phenotypes of HCM are more varied in children, but few data are available in literature. The aim of our study was to identify the clinical characteristics and the different etiologies of HCM in children in pediatric cardiology department of the Rabta hospital over two decades. Methods: This retrospective study performed in the pediatric cardiology department of the Rabta hospital enrolled all patients aged under 18 years old, hospitalized for hypertrophic cardiomyopathy during January 1999 to July 2020. We studied etiological and clinical features of these disease. Results: Fifty-seven children were included during the last twenty years. The median age at diagnosis was 1,4 years, 46% of patients were aged under one year old. The sex ratio was 1,27. The male predominance was marked in children over 10 years of age. The diagnosis of idiopathic HCM was made in 60% of patients, divided into familial HCM in 28% and sporadic HCM in 32% of patients. Inborn error of metabolism (IEM) was found in 25% of patients: Glycogen storage disease type III and Pompe disease were the most common disorders. The diagnosis of RASopathy was made in 14% of patients: seven patients was diagnosed with Noonan Syndrome and a patient was diagnosed with Costello syndrome. 2% of patients had neuromuscular disease (Friedreich’s ataxia). Twenty-five patients (48%) had a first or second-degree. Relative with HCM based on family history; of these, 64% had an idiopathic HCM. Heart failure signs were present in 9% of patients, they were more common in patients presenting in infancy. Non sustained ventricular tachycardia was found in 9% of patients. Concentric hypertrophy was present in 58% of patient, especially in patients with IEM. 92% of patients with IEM had non obstructive HCM. Conclusions: These results suggest that HCM in children is a heterogenous disease in terms of its age of presentation, aetiology and clinical presentation. An improved understanding of the relationship between different aetiologies and clinical presentation will facilitate the treatment and follow-up of these patients.
RkJQdWJsaXNoZXIy NDIzNzc=